Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

AN OPEN-LABEL MECHANISTIC STUDY TO ASSESS THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF ORALLY ADMINISTERED EPELEUTON IN PATIENTS WITH SICKLE CELL DISEASE

Intervention/treatment:
EPELEUTON (DS102)
Medical condition:
SICKLE CELL DISEASE
Protocol code:
DS102A-10-RD2
Control number:
288156
Status:
Closed
Approved:
July 31, 2024
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05861453
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
AFIMMUNE LIMITED

Locations

British Columbia

St Paul's Hospital Hematology/Oncology Research
Vancouver, British Columbia, V6E 1M7

Ontario

Toronto General Hospital
Toronto, Ontario, M5G 2C4
Did you find what you were looking for?